|
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Clinical research trials and SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck. SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck clinical trial. Test subjects typically obtain the finest healthcare available for their SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck  SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
For Condition: lip and oral cavity cancer,Head and Neck Cancer,Oropharyngeal Cancer,Skin Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.
Details: OBJECTIVES: I. Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck. II. Determine the safety and toxicity of SU5416 in these patients. PROTOCOL OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 1 year. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically proven epidermoid/squamous cell carcinoma of the oral cavity, lip, hypopharynx, oropharynx, nasopharynx, sinonasal tract, or larynx; undifferentiated carcinoma of the nasopharynx (WHO type III); sinonasal undifferentiated carcinoma; or squamous cell carcinoma of unknown primary or the skin with initial presentation in the head and neck region Advanced or recurrent disease that is incurable with surgery or radiotherapy No more than 2 prior cytotoxic chemotherapy regimens for recurrent, persistent, or metastatic disease - Prior exposure to chemopreventive agents (e.g., tretinoin or other vitamin analogues) is not considered to be a prior cytotoxic chemotherapy exposure At least 1 measurable indicator lesion - Bone metastases, elevated enzyme levels, or lesions on radionuclide scans are not acceptable as the sole parameters of measurable disease No history of brain metastases --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: - See Disease Characteristics - More than 4 weeks since prior radiotherapy Surgery: See Disease Characteristics --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: - WBC greater than 3,000/mm3 - Hemoglobin greater than 8 g/dL - Platelet count greater than 100,000/mm3 - No history of coagulation disorder Hepatic: - Bilirubin normal - SGOT less than 2.5 times upper limit of normal - PT no greater than 14 seconds - aPTT no greater than 40 seconds Renal: - Creatinine less than 1.5 mg/dL OR - Creatinine clearance at least 60 mL/min Cardiovascular: - No uncompensated coronary artery disease - No myocardial infarction or severe/unstable angina within the past 6 months - No severe peripheral vascular disease associated with diabetes mellitus - No deep venous or arterial thrombosis within the past 3 months - No unstable cardiac rhythm - No cerebrovascular accident within the past 6 months Pulmonary: No pulmonary embolism within the past 3 months Other: - No history of allergic reaction to paclitaxel - No other active malignancy except basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or synchronous epidermoid/squamous cell carcinoma of the head and neck (oral cavity, lip, hypopharynx, oropharynx, nasopharynx, sinonasal tract, or larynx) - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No active bacterial infection requiring antibiotics - No other concurrent medical condition that would increase risk
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidPfister, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000068232; MSKCC-00049,NCI-79
Study Start Date: December 2000
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006361
Other Lip And Oral Cavity Cancer Studies:
1. Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
2. Chemotherapy With or Without Gene Therapy in Treating Patients With Unresectable Recurrent Head and Neck Cancer
3. Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer
4. Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
5. Flavopiridol in Treating Patients With Metastatic or Unresectable Mantle Cell Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, or Invasive Breast Cancer
Related Studies:
Other lip and oral cavity cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
|
|
|
|
|
|
|
|
